Allergic diseases such as allergic rhinitis (AR), allergic asthma (AAS), atopic dermatitis (AD),
food allergy (FA), and eczema are systemic diseases caused by an impaired immune …

Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple
interacting systems. In AD, skin inflammation is caused by host–environment interactions …

Background Pivotal phase III studies demonstrated that abrocitinib, an oral, once-daily, JAK1-
selective inhibitor, is effective treatment for moderate-to-severe atopic dermatitis (AD) as …

The incidence of allergic diseases is increasing, and research on their epidemiology,
pathophysiology, and the prevention of onset is urgently needed. The onset of allergic …

Summary Background Interleukin (IL)‐31 affects the inflammatory response, is involved in
epidermal barrier disruption in atopic dermatitis (AD) and plays a key role in pruritus …

Atopic dermatitis (AD) is a skin disease that is heterogeneous both in terms of clinical
manifestations and molecular profiles. It is increasingly recognized that AD is a systemic …

Background IL-31 is a type 2 cytokine involved in the itch sensation in atopic dermatitis (AD).
The cellular origins of IL-31 are generally considered to be TH 2 cells. Macrophages have …

Recently, Jak inhibitors such as baricitinib, upadacitinib, and abrocitinib were approved for
the treatment of atopic dermatitis (AD) in addition to biologics, including dupilumab …

We evaluated the efficacy and safety of upadacitinib, janus kinase 1 inhibitor for atopic
dermatitis (AD) in real‐world practice. From September 2021 to March 2022, 31 patients with …

Mast cells are present in all vascularized tissues of the body. They are especially abundant
in tissues that are in frequent contact with the surrounding environment and act as potential …